(Q31051809)

English

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

anti-retroviral agent

0 references

0 references

1 reference

based on heuristic

inferred from title

Christine Katlama

5

object named as

Christine Katlama

0 references

Adriano Lazzarin

object named as

Adriano Lazzarin

7

0 references

Bonaventura Clotet Sala

6

object named as

Bonaventura Clotet

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Sharon Walmsley

1 reference

ORCID Public Data File 2021

2

object named as

Pedro Cahn

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

author name string

Charles B Hicks

1

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

David A Cooper

3

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Sharon L Walmsley

4

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Margaret A Johnson

8

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Dietmar Neubacher

9

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Douglas Mayers

10

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Hernan Valdez

11

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

RESIST investigator group

12

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

language of work or name

0 references

publication date

1 August 2006

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

368

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

9534

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

466-475

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Determinants of virological response to antiretroviral therapy: implications for long-term strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969154-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(06)69154-X

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31051809&oldid=2108308287"